Skip to content

NEI Research News

Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.

852 items
National Eye Institute logo.

Avastin and Lucentis are equivalent in treating age-related macular degeneration

At two years, Avastin (bevacizumab) and Lucentis (ranibizumab injection), two widely used drugs to treat age-related macular degeneration (AMD).
National Eye Institute logo.

NEI-funded Scientists Create "New Eye Tissues" from Blood Cells in a Petri Dish

Researchers recently demonstrated that human blood cells can be converted into a variety of eye cells important for vision.
National Eye Institute logo.

New App to the Help the Blind Recognize Objects

NantWorks LLC has released the new LookTel Recognizer app designed to help people who are blind or visually impaired recognize everyday objects by using their iPhone camera.
National Eye Institute logo.

Decorative Contact Lenses

Around Halloween time, health experts fear that consumers will harm their eyes with unapproved decorative contact lenses.
National Eye Institute logo.

Funded by National Eye Institute, Makers of Bionic Eye Receive Eight Millionth Patent

The Argus II retinal prosthesis, developed by Second Sight, Inc., with funding from the National Eye Institute (NEI), was recognized September 8, 2011, in honor of being the 8 millionth patent issued by the United States Patent and Trademark Office.
National Eye Institute logo.

National Institutes of Health releases data from largest pediatric eye study

Study estimates prevalence of vision disorders among preschool children in three ethnic groups, identifies risk factors
NIH National Eye Institute logo

NIH study shows two treatments for uveitis equally effective

Treating patients with severe cases of uveitis, the fifth leading cause of vision loss in the United States, either locally with eye implants or systemically with anti-inflammatory medications improved vision similarly over two years.
National Eye Institute logo.

NIH study finds Avastin and Lucentis are equally effective in treating age-related macular degeneration

Researchers are reporting results from the first year of a two-year clinical trial that Avastin, a drug approved to treat some cancers and that is commonly used off-label to treat age-related macular degeneration (AMD).
National Eye Institute logo.

LASIK Quality of Life Collaboration Project

In October 2009, the FDA, the National Eye Institute, and the Department of Defense launched the LASIK Quality of Life Collaboration Project.
National Eye Institute logo.

NIH adds first images to major research database

More than 72,000 clinical photographs illustrate age-related eye disease progression